Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Richard E. Pratley MD Associate Editor

Deborah J. Wexler MD, MSc Associate Editor

Silvio E. Inzucchi MD Editor-in-Chief

See All Experts

featured

Published in Diabetes

Expert Opinion / Commentary · December 10, 2024

2024 Top Story in Diabetes: The SELECT Trial

Written by

Silvio E. Inzucchi MD

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232.

Disclosure statements are available on the authors' profiles:

Silvio Inzucchi MD

story of the week

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes — 2025

Diabetes Care · December 19, 2024
featured

Role of Intermittent Fasting in Weight Management and Improving Metabolic Health

Diabetes Obes Metab · December 19, 2024
featured

Consensus Considerations and Good Practice Points for the Use of CGM Systems in Hospital Settings

Diabetes Care · December 19, 2024
featured

Weight Changes After Treatment With Semaglutide in Individuals With MASLD/MASH With or Without Type 2 Diabetes

Diabetes Obes Metab · December 18, 2024
featured

Potential Off-Label Indication of Metformin for Ischaemic Stroke

Diabetes Obes Metab · December 18, 2024
featured

GLP-1 Agonists Combined With GIP and/or GCG Agonists vs GLP-1 Agonists Alone for Weight Loss in Adults With Obesity Without Type 2 Diabetes

Diabetes Obes Metab · December 18, 2024
featured

Effect of Long-Term Glycemic Burden on the Incidence of Diabetic Foot Ulcers

J Diabetes Complicat · December 17, 2024
featured

Weight Maintenance Using Cost-Effective Antiobesity Medications After 1 Year of GLP-1 Receptor Agonist Therapy

Obesity · December 15, 2024

updated
featured

Trends in the Incidence of Young Adult–Onset Diabetes by Diabetes Type

Lancet Diabetes Endocrinol · December 15, 2024

updated
featured

Prognosis of Severe Hypoglycaemia and Diabetic Ketoacidosis in Adults Presenting to an Emergency Department

Diabet. Med. · December 14, 2024

updated
featured

Perinatal Outcomes in Patients With Early vs Late Gestational Diabetes Mellitus Treated Between 24 and 28 Weeks of Gestation

Diabetes Care · December 14, 2024

2024 Top Story in Diabetes: The SELECT Trial

Additional Info

Further Reading

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes — 2025

Role of Intermittent Fasting in Weight Management and Improving Metabolic Health

Consensus Considerations and Good Practice Points for the Use of CGM Systems in Hospital Settings

Weight Changes After Treatment With Semaglutide in Individuals With MASLD/MASH With or Without Type 2 Diabetes

Potential Off-Label Indication of Metformin for Ischaemic Stroke

GLP-1 Agonists Combined With GIP and/or GCG Agonists vs GLP-1 Agonists Alone for Weight Loss in Adults With Obesity Without Type 2 Diabetes

Effect of Long-Term Glycemic Burden on the Incidence of Diabetic Foot Ulcers

Weight Maintenance Using Cost-Effective Antiobesity Medications After 1 Year of GLP-1 Receptor Agonist Therapy

Trends in the Incidence of Young Adult–Onset Diabetes by Diabetes Type

Prognosis of Severe Hypoglycaemia and Diabetic Ketoacidosis in Adults Presenting to an Emergency Department

Perinatal Outcomes in Patients With Early vs Late Gestational Diabetes Mellitus Treated Between 24 and 28 Weeks of Gestation

Recently Updated